Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

a Phase 2/3 clinical study of NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS) as part of the HEALEY ALS Platform Trial

Next Previous
X
Search
Trial Profile

a Phase 2/3 clinical study of NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS) as part of the HEALEY ALS Platform Trial

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 14 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Monepantel (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Acronyms HEALEY ALS

    • Most Recent Events

    • 14 Nov 2024 New trial record
    • 11 Nov 2024 According to the Neurizon Therapeutics Media Release, company plans this trial as part of the HEALEY ALS Platform Trial with patient enrolment expected to commence in early H1 CY2025.
    • 15 Oct 2024 According to the Neurizon Therapeutics media release, PharmAust has changed its name to Neurizon Therapeutics.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top